AIM ImmunoTech Inc. (0A4Y)
LSE
Closed
Oct 7, 2026
Day's Range
0.180052 wk Range
0.1700Overview - 0A4Y - AIM ImmunoTech Inc.
Key Statistics
Valuation
Enterprise Value
-131.13K
P/E (Trailing)
‪6.00‬
Price / Book
‪0.71‬
EV / EBITDA
‪0.01‬
Profitability
Profit Margin
‪19.75%‬
Operating Margin
‪-13,511.53%‬
Return on Assets
‪-82.57%‬
Return on Equity
‪-2,382.30%‬
Ownership
Shares Outstanding
101.97M
Float
27.64M
Held by Insiders
‪0.74%‬
Held by Institutions
‪3.87%‬
Price stats
Beta
‪1.18‬
50-Day Avg
‪0.4790‬
200-Day Avg
‪0.5130‬
Peers - 0A4Y - AIM ImmunoTech Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0A4YLSEAIM ImmunoTech Inc.-1289.87%52-week change6.01P/E (Trailing)‪19.75%‬Profit Margin
- 0A45LSEModerna Inc.+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0RU5LSEOncoinvent ASA+98.57%52-week change350.00P/E (Trailing)‪34.25%‬Profit Margin
- 0JDKLSEIovance Biotherapeutics Inc.+84.26%52-week change25.49P/E (Trailing)‪-89.09%‬Profit Margin
- 0GQULSEActive Biotech AB+96.20%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0RISLSECircio Holding ASA+94.15%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0NWKLSEValerio Tx Corp.+89.13%52-week change1.27P/E (Trailing)‪-190.36%‬Profit Margin
Profile Summary - 0A4Y - AIM ImmunoTech Inc.
About
AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
